Sign in Subscribe
Cancer

Breakthrough in Brain Metastasis Treatment: Novel Therapy Sustains Remission for 16 Months

Strategic Insights

— 2 min read

A study published in the Journal of Obstetrics and Gynaecology Research has reported a groundbreaking case of brain metastasis treatment using a combination of lenvatinib and pembrolizumab. The 43-year-old patient, who had endometrial cancer with mismatch repair deficiency, developed multiple brain metastases despite chemotherapy. However, after receiving stereotactic radiotherapy, followed by combination therapy with lenvatinib and pembrolizumab, the patient achieved sustained partial remission for 16 months, with no evidence of brain hemorrhage.

Key Takeaways:

  • The study presents a rare case of brain metastases from endometrial carcinoma, with a poor prognosis but remarkable response to novel therapy.
  • The patient's condition was characterized by mismatch repair deficient endometrial cancer, which made her resistant to conventional chemotherapy.
  • Stereotactic radiotherapy was used as a bridge to combination therapy with lenvatinib and pembrolizumab, which resulted in sustained partial remission for 16 months.
  • The study highlights the potential of lenvatinib plus pembrolizumab as an effective and safe therapeutic option for brain metastases from endometrial cancer, even in patients resistant to conventional therapy.
  • The case challenges the traditionally poor prognosis of brain metastases from endometrial cancer and underscores the importance of novel targeted and immunotherapeutic strategies.
  • The study's findings suggest that combination therapy with lenvatinib and pembrolizumab may redefine the standard of care for this rare and devastating complication.
  • The research was conducted by investigators at Shiga University of Medical Sciences, with collaboration from researchers at other institutions.
  • The study's authors include Akimasa Takahashi, Ayaka Fujioka, Tsukuru Amano, Yuji Tanaka, Yutaka Yoneoka, and Shunichiro Tsuji.

Statistics:

  • The patient's age was 43 years at the time of diagnosis.
  • The duration of sustained partial remission was 16 months.
  • The patient's condition was characterized by mismatch repair deficient endometrial cancer.
  • The number of brain metastases was not specified.
  • The patient's response to conventional chemotherapy was unsuccessful.
  • The study's findings were published in the Journal of Obstetrics and Gynaecology Research (51(10), 2025).
  • The study's authors reported that combination therapy with lenvatinib and pembrolizumab resulted in sustained partial remission, with no evidence of brain hemorrhage.

Sources:

  • Long Term Disease Control of Brain Metastases From Chemotherapy-Resistant Endometrial Cancer With Lenvatinib and Pembrolizumab: A Case Report. Journal of Obstetrics and Gynaecology Research, 2025;51(10).
  • Akimasa Takahashi, Ayaka Fujioka, Tsukuru Amano, Yuji Tanaka, Yutaka Yoneoka, and Shunichiro Tsuji. Publisher contact information for the Journal of Obstetrics and Gynaecology Research is: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA.
  • NewsRx. Findings on Brain Metastasis Detailed by Researchers at Shiga University of Medical Sciences (Long Term Disease Control of Brain Metastases From Chemotherapy-Resistant Endometrial Cancer With Lenvatinib and Pembrolizumab: A Case Report). OBGYN & Reproduction Week. October 27, 2025; p 260.

Read more